Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis

Abstract

Delaying anti-CD20 start to monitor ALC after S1P modulator discontinuation may not be necessary and could increase rebound risk. ALC monitoring could instead occur after a rapid switch to anti-CD20 treatment.